Related Experiment Video

Updated: May 24, 2026

Histological Quantification of Chronic Myocardial Infarct in Rats
09:45

Histological Quantification of Chronic Myocardial Infarct in Rats

Published on: December 11, 2016

Cardiomyocyte size estimated from noninvasive measurements of left ventricular wall thickness and chamber diameter

Richard E Tracy1

  • 1Department of Pathology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA. rtracy@lsuhsc.edu

Journal of the American Society of Hypertension : JASH
|March 16, 2012
PubMed

Insights

This study introduces a new equation to estimate cardiomyocyte size using noninvasive measurements, improving the assessment of left ventricular hypertrophy (LVH) and aiding research into cardiac hypertrophy mechanisms.

Area of Science:

  • Cardiovascular pathology
  • Cardiac imaging
  • Histopathology

Background:

  • Noninvasive measures of left ventricular wall thickness (LVT) and chamber diameter (LVD) estimate left ventricular weight (LVW) but not myocyte breadth (MyB).
  • This limits optimal determination of left ventricular hypertrophy (LVH).

Purpose of the Study:

  • To develop a method for predicting myocyte breadth (MyB) from noninvasive measurements.
  • To enhance the diagnostic accuracy of left ventricular hypertrophy (LVH) assessment.
  • To generate hypotheses regarding the mechanisms of cardiac hypertrophy.

Main Methods:

  • Derived a regression equation to predict MyB from LVT and LVD using postmortem data from 78 forensic autopsies.
  • Validated the equation by applying it to clinical data from published studies.

Main Results:

  • The derived regression equation accurately predicted myocyte sizes.
  • Predictions from clinical data showed a scatter plot closely resembling the postmortem dataset.
  • This method offers a provisional improvement for LVH determination using noninvasive imaging.

Conclusions:

  • The developed equation provides a valid prediction of cardiomyocyte sizes.
  • This approach may enhance the noninvasive assessment of left ventricular hypertrophy (LVH).
  • Further validation is required, but this method offers a promising tool for understanding cardiac hypertrophy.

More Related Videos

Using Chicken Embryo as a Powerful Tool in Assessment of Developmental Cardiotoxicities11:00

Using Chicken Embryo as a Powerful Tool in Assessment of Developmental Cardiotoxicities

Published on: March 21, 2021

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography08:13

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Published on: February 16, 2016

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...